Liver Cancer Therapeutics Market, By Therapeutic Modality, By Drug Type, By Treatment Line, By Geography

Description

Liver Cancer Therapeutics Market is estimated to be valued at USD 8.98 billion in 2026 and is expected to reach USD 16.95 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.5% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 8.98 billion
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	9.50%	2033 Value Projection:	USD 16.95 billion

The global liver cancer therapeutics market covers a broad set of therapeutic modality categories, including Targeted Therapy, Immunotherapy, and Chemotherapy, used across applications such as Small Molecules, Monoclonal Antibodies, and Antibody-Drug Conjugates (ADC). Demand is supported by adoption among First Line, and Second Line and the need for more efficient, reliable solutions. Continued technological advancement and rising end-user requirements are shaping the growth of this market.

Market Dynamics:

Growing adoption across Small Molecules, and Monoclonal Antibodies, rising end-user demand, and a continued focus on improving efficiency and performance are major factors expected to drive growth of the global liver cancer therapeutics market. A wider range of available options is making these solutions accessible to a broader base of users.

For instance, companies are expanding their portfolios to address evolving requirements across First Line, and Second Line. Moreover, increasing investment in innovation and new technology integration is expected to create new growth opportunities for market players over the forecast period.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global liver cancer therapeutics market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Gilead Sciences, Bristol-Myers Squibb, Bayer AG, Merck & Co., Novartis AG, Eisai Co, Ltd., AstraZeneca PLC, Pfizer Inc., Ipsen, Exelixis, NGM Biopharmaceuticals, HUTCHMED, Zai Lab, Genfit, and BeiGene, among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global liver cancer therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global liver cancer therapeutics market.

Detailed Segmentation:

Global Liver Cancer Therapeutics Market, By Therapeutic Modality (Revenue, USD Bn, 2021 - 2033)
Targeted Therapy
Immunotherapy
Chemotherapy
Locoregional Therapy
Others
Global Liver Cancer Therapeutics Market, By Drug Type (Revenue, USD Bn, 2021 - 2033)
Small Molecules
Monoclonal Antibodies
Antibody-Drug Conjugates (ADC)
Cell-based Therapies
Others
Global Liver Cancer Therapeutics Market, By Treatment Line (Revenue, USD Bn, 2021 - 2033)
First Line
Second Line
Third Line and Beyond
Others
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Company Profiles:
Gilead Sciences*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
Bristol-Myers Squibb
Bayer AG
Merck & Co.
Novartis AG
Eisai Co, Ltd.
AstraZeneca PLC
Pfizer Inc.
Ipsen
Exelixis
NGM Biopharmaceuticals
HUTCHMED
Zai Lab
Genfit
BeiGene

"*" marked represents similar segmentation in other categories in the respective section.

Product Code: CMI1591

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Preview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Therapeutic Modality
- Market Snapshot, By Drug Type
- Market Snapshot, By Treatment Line
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaboration
Regulatory Scenario
Key Developments
PEST Analysis
Partnership Scenario
Brand and Pricing Analysis
Distributors Landscape
Porters Analysis
Technological Advancements
Key Developments
Market Trend
Future Prospective
Top Market Players by Revenue

4. Liver Cancer Therapeutics Market By Therapeutic Modality, 2026-2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Locoregional Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

5. Liver Cancer Therapeutics Market By Drug Type, 2026 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Small Molecules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Antibody-Drug Conjugates (ADC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Cell-based Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

6. Liver Cancer Therapeutics Market By Treatment Line, 2026 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
First Line
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Second Line
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Third Line and Beyond
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)

7. Liver Cancer Therapeutics Market By Region, 2026 - 2033, (US$ Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Line, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Line, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Line, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Benelux
  - Denmark
  - Norway
  - Sweden
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Line, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
  - China
  - Taiwan
  - India
  - Japan
  - Indonesia
  - Malaysia
  - Philippines
  - Singapore
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Therapeutic Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Line, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
Bahrain
Kuwait
Oman
Qatar
Saudi Arabia
UAE
Israel
South Africa
North Africa
Central Africa
Rest of the Middle East

1. Competitive Landscape

Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Ipsen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Exelixis
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
NGM Biopharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
HUTCHMED
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Zai Lab
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
Genfit
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
BeiGene
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies

2. Section

Research Methodology
About Us